Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol

Eva Reihnér, Mats Rudling, Dagny Ståhlberg, Lars Berglund, Staffan Ewerth, Ingemar Björkhem, Kurt Einarsson, Bo Angelin

Research output: Contribution to journalArticle

220 Citations (Scopus)

Abstract

Background. Inhibitors of the rate-limiting enzyme of cholesterol biosynthesis, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, are now used frequently to treat hypercholesterolemia. We studied the effects of specific inhibition of cholesterol synthesis by one of these agents (pravastatin) on the hepatic metabolism of cholesterol in patients with gallstone disease who were scheduled to undergo cholecystectomy. Methods. Ten patients were treated with pravastatin (20 mg twice a day) for three weeks before cholecystectomy; 20 patients not treated served as controls. A liver specimen was obtained from each patient at operation, and the activities of rate-determining enzymes in cholesterol metabolism as well as low-density-lipoprotein (LDL)-receptor binding activity were determined. Results. Pravastatin therapy reduced plasma total cholesterol by 26 percent and LDL cholesterol by 39 percent (P<0.005). Serum levels of free lathosterol, a precursor of cholesterol whose concentration reflects the rate of cholesterol synthesis in vivo, decreased by 63 percent (P<0.005), indicating reduced de novo biosynthesis of cholesterol. Microsomal HMG-CoA reductase activity, when analyzed in vitro in the absence of the inhibitor, was increased 11.8-fold (1344±311 vs. 105±14 pmol per minute per milligram of protein in the controls; P<0.001). The expression of LDL receptors was increased by 180 percent (P<0.005), whereas the activities of cholesterol 7α-hydroxylase (which governs bile acid synthesis) and of acyl-coenzyme A:cholesterol O-acyltransferase (which regulates cholesterol esterification) were unaffected by treatment. Conclusions. Inhibition of hepatic HMG-CoA reductase by pravastatin results in an increased expression of hepatic LDL receptors, which explains the lowered plasma levels of LDL cholesterol.

Original languageEnglish (US)
Pages (from-to)224-228
Number of pages5
JournalNew England Journal of Medicine
Volume323
Issue number4
StatePublished - Jul 26 1990
Externally publishedYes

Fingerprint

Pravastatin
Oxidoreductases
Cholesterol
Liver
LDL Receptors
Cholecystectomy
LDL Cholesterol
Cholesterol 7-alpha-Hydroxylase
Sterol O-Acyltransferase
3-hydroxy-3-methylglutaryl-coenzyme A
Acyl Coenzyme A
Esterification
Gallstones
Enzymes
Hypercholesterolemia
Bile Acids and Salts

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Reihnér, E., Rudling, M., Ståhlberg, D., Berglund, L., Ewerth, S., Björkhem, I., ... Angelin, B. (1990). Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. New England Journal of Medicine, 323(4), 224-228.

Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. / Reihnér, Eva; Rudling, Mats; Ståhlberg, Dagny; Berglund, Lars; Ewerth, Staffan; Björkhem, Ingemar; Einarsson, Kurt; Angelin, Bo.

In: New England Journal of Medicine, Vol. 323, No. 4, 26.07.1990, p. 224-228.

Research output: Contribution to journalArticle

Reihnér, E, Rudling, M, Ståhlberg, D, Berglund, L, Ewerth, S, Björkhem, I, Einarsson, K & Angelin, B 1990, 'Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol', New England Journal of Medicine, vol. 323, no. 4, pp. 224-228.
Reihnér, Eva ; Rudling, Mats ; Ståhlberg, Dagny ; Berglund, Lars ; Ewerth, Staffan ; Björkhem, Ingemar ; Einarsson, Kurt ; Angelin, Bo. / Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. In: New England Journal of Medicine. 1990 ; Vol. 323, No. 4. pp. 224-228.
@article{f5e1ab97c1e94b129dbb4d30038ef77d,
title = "Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol",
abstract = "Background. Inhibitors of the rate-limiting enzyme of cholesterol biosynthesis, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, are now used frequently to treat hypercholesterolemia. We studied the effects of specific inhibition of cholesterol synthesis by one of these agents (pravastatin) on the hepatic metabolism of cholesterol in patients with gallstone disease who were scheduled to undergo cholecystectomy. Methods. Ten patients were treated with pravastatin (20 mg twice a day) for three weeks before cholecystectomy; 20 patients not treated served as controls. A liver specimen was obtained from each patient at operation, and the activities of rate-determining enzymes in cholesterol metabolism as well as low-density-lipoprotein (LDL)-receptor binding activity were determined. Results. Pravastatin therapy reduced plasma total cholesterol by 26 percent and LDL cholesterol by 39 percent (P<0.005). Serum levels of free lathosterol, a precursor of cholesterol whose concentration reflects the rate of cholesterol synthesis in vivo, decreased by 63 percent (P<0.005), indicating reduced de novo biosynthesis of cholesterol. Microsomal HMG-CoA reductase activity, when analyzed in vitro in the absence of the inhibitor, was increased 11.8-fold (1344±311 vs. 105±14 pmol per minute per milligram of protein in the controls; P<0.001). The expression of LDL receptors was increased by 180 percent (P<0.005), whereas the activities of cholesterol 7α-hydroxylase (which governs bile acid synthesis) and of acyl-coenzyme A:cholesterol O-acyltransferase (which regulates cholesterol esterification) were unaffected by treatment. Conclusions. Inhibition of hepatic HMG-CoA reductase by pravastatin results in an increased expression of hepatic LDL receptors, which explains the lowered plasma levels of LDL cholesterol.",
author = "Eva Reihn{\'e}r and Mats Rudling and Dagny St{\aa}hlberg and Lars Berglund and Staffan Ewerth and Ingemar Bj{\"o}rkhem and Kurt Einarsson and Bo Angelin",
year = "1990",
month = "7",
day = "26",
language = "English (US)",
volume = "323",
pages = "224--228",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "4",

}

TY - JOUR

T1 - Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol

AU - Reihnér, Eva

AU - Rudling, Mats

AU - Ståhlberg, Dagny

AU - Berglund, Lars

AU - Ewerth, Staffan

AU - Björkhem, Ingemar

AU - Einarsson, Kurt

AU - Angelin, Bo

PY - 1990/7/26

Y1 - 1990/7/26

N2 - Background. Inhibitors of the rate-limiting enzyme of cholesterol biosynthesis, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, are now used frequently to treat hypercholesterolemia. We studied the effects of specific inhibition of cholesterol synthesis by one of these agents (pravastatin) on the hepatic metabolism of cholesterol in patients with gallstone disease who were scheduled to undergo cholecystectomy. Methods. Ten patients were treated with pravastatin (20 mg twice a day) for three weeks before cholecystectomy; 20 patients not treated served as controls. A liver specimen was obtained from each patient at operation, and the activities of rate-determining enzymes in cholesterol metabolism as well as low-density-lipoprotein (LDL)-receptor binding activity were determined. Results. Pravastatin therapy reduced plasma total cholesterol by 26 percent and LDL cholesterol by 39 percent (P<0.005). Serum levels of free lathosterol, a precursor of cholesterol whose concentration reflects the rate of cholesterol synthesis in vivo, decreased by 63 percent (P<0.005), indicating reduced de novo biosynthesis of cholesterol. Microsomal HMG-CoA reductase activity, when analyzed in vitro in the absence of the inhibitor, was increased 11.8-fold (1344±311 vs. 105±14 pmol per minute per milligram of protein in the controls; P<0.001). The expression of LDL receptors was increased by 180 percent (P<0.005), whereas the activities of cholesterol 7α-hydroxylase (which governs bile acid synthesis) and of acyl-coenzyme A:cholesterol O-acyltransferase (which regulates cholesterol esterification) were unaffected by treatment. Conclusions. Inhibition of hepatic HMG-CoA reductase by pravastatin results in an increased expression of hepatic LDL receptors, which explains the lowered plasma levels of LDL cholesterol.

AB - Background. Inhibitors of the rate-limiting enzyme of cholesterol biosynthesis, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, are now used frequently to treat hypercholesterolemia. We studied the effects of specific inhibition of cholesterol synthesis by one of these agents (pravastatin) on the hepatic metabolism of cholesterol in patients with gallstone disease who were scheduled to undergo cholecystectomy. Methods. Ten patients were treated with pravastatin (20 mg twice a day) for three weeks before cholecystectomy; 20 patients not treated served as controls. A liver specimen was obtained from each patient at operation, and the activities of rate-determining enzymes in cholesterol metabolism as well as low-density-lipoprotein (LDL)-receptor binding activity were determined. Results. Pravastatin therapy reduced plasma total cholesterol by 26 percent and LDL cholesterol by 39 percent (P<0.005). Serum levels of free lathosterol, a precursor of cholesterol whose concentration reflects the rate of cholesterol synthesis in vivo, decreased by 63 percent (P<0.005), indicating reduced de novo biosynthesis of cholesterol. Microsomal HMG-CoA reductase activity, when analyzed in vitro in the absence of the inhibitor, was increased 11.8-fold (1344±311 vs. 105±14 pmol per minute per milligram of protein in the controls; P<0.001). The expression of LDL receptors was increased by 180 percent (P<0.005), whereas the activities of cholesterol 7α-hydroxylase (which governs bile acid synthesis) and of acyl-coenzyme A:cholesterol O-acyltransferase (which regulates cholesterol esterification) were unaffected by treatment. Conclusions. Inhibition of hepatic HMG-CoA reductase by pravastatin results in an increased expression of hepatic LDL receptors, which explains the lowered plasma levels of LDL cholesterol.

UR - http://www.scopus.com/inward/record.url?scp=0025345124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025345124&partnerID=8YFLogxK

M3 - Article

VL - 323

SP - 224

EP - 228

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 4

ER -